To evaluate the frequency, clinical features, and prognosis of patients with osteitis caused by bacille Calmette-Guérin (BCG) vaccination, medical records from Finnish children based on nationwide registration from 1960 to 1988 were retrospectively analyzed. During the study period, three different BCG vaccine preparations were used. In 222 children, diagnostic criteria of BCG osteitis were fulfilled. The age at onset of BCG osteitis varied from 0.25 to 5.7 years. The most common sites of osteitis were metaphyses of the long bones. The lower extremity (58%) was affected more often than the upper (14%). Osteitis was situated in the sternum in 36 patients (15%) and in the ribs in 27 (11%). The frequency of BCG osteitis, but not the clinical parameters, was closely associated with the vaccine preparation used. Only 6 children were left with some sequelae. With adequate treatment, the prognosis for children vaccinated with BCG is good.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/infdis/172.2.574 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of Bacille Calmette-Guérin vaccination on the therapeutic schedule of infantile epileptic spasms syndrome: A 25-year Japanese single-center survey.
Vaccine X
October 2024
Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
Adrenocorticotropic hormone (ACTH) therapy is effective for infantile epileptic spasms syndrome (IESS) but can induce immunosuppression. In Japan, Bacille Calmette-Guérin (BCG) vaccination, modified in 2013 to reduce osteitis/osteomyelitis risk, coincides with the peak onset age of IESS. This raises concerns about infection risks when administering ACTH therapy post-vaccination.
View Article and Find Full Text PDFOsteitis of the radius after bacillus Calmette-Guèrin vaccination in international adopted children.
Minerva Pediatr (Torino)
October 2024
Unit of Infectious Diseases, Department of Pediatrics and Public Health Sciences, Regina Margherita Children's Hospital, Città della Salute e della Scienza, University of Turin, Turin, Italy.
Typical time courses and appearance of skin reactions at the site of Bacillus Calmette-Guérin vaccination for infants inoculated at 5-8 months of age.
Vaccine
February 2023
Department of Pediatrics, MacKay Children's Hospital and MacKay Memorial Hospital, Taipei, Taiwan; Department of Medicine, MacKay Medical College, New Taipei, Taiwan; MacKay Junior College of Medicine, Nursing and Management, Taipei, Taiwan. Electronic address:
Background: Taiwan increased the Bacillus Calmette-Guerin (BCG) vaccination age from 24 h after birth to 5-8 months of age to lower BCG-related osteitis/osteomyelitis in 2016. However, the sequences of skin changes at the injection site and in the corresponding lymph nodes are unknown for infants vaccinated at an older age.
Methods: We prospectively collected the photographs of skin reactions within 6 months after vaccination.
Characteristics and incidence of vaccine adverse events after Bacille Calmette-Guérin vaccination: A national surveillance study in Japan from 2013 to 2017.
Vaccine
August 2022
Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Tokyo, Japan. Electronic address:
Article Synopsis
- Japan revised the recommended age for BCG vaccinations multiple times from under 6 months to 5-8 months due to rising cases of BCG-related osteitis/osteomyelitis since 2005.
- Data on adverse events from BCG vaccinations in infants <1 year were collected from April 2013 to March 2017, comparing events in those vaccinated before and after reaching 6 months.
- Findings showed a higher incidence of osteitis/osteomyelitis in infants vaccinated at <6 months, suggesting the age adjustment in 2013 likely helped reduce these adverse effects.
Tubercular Spondylitis: A Rare Complication of BCGosis Masquerading as Metastasis on 18F-PSMA-1007 PET/CT.
Clin Nucl Med
March 2022
From the Department of Nuclear Medicine, Royal Liverpool University Hospital.
BCGosis is a rare complication of intravesical BCG immunotherapy as adjuvant therapy for urinary bladder cancer manifesting in the form of disseminated tuberculosis or organ-specific tuberculosis, rarely involving the vertebra. PSMA is overexpressed in prostate cancer but also expressed in a variety of benign and malignant conditions. We present a patient with incidental detection of abnormal uptake in a vertebral lesion during assessment of prostate cancer with 18F-PSMA PET/CT, subsequently proven to be vertebral osteitis, likely due to BCG immunotherapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!